CADTH recommends medical abortion reimbursement

Statement of Vicki Saporta, President and CEO of the National Abortion Federation Canada on the Canadian Agency for Drugs and Technologies in Health (CADTH) recommendation on Mifegymiso: We are pleased that CADTH has recommended that mifepristone and misoprostol be reimbursed for medical abortion care. CADTH’s recommendation will help make medical abortion care more widely accessible…

Read More

New FDA label for medical abortion pill, Mifeprex

Statement by Vicki Saporta, President and CEO of the National Abortion Federation (NAF), on the New FDA Label for Medical Abortion Pill, Mifeprex: We are delighted that the FDA has approved a label change, which brings the label for mifepristone in-line with scientific research and evidence-based practice. Since mifepristone was initially approved by the FDA…

Read More